Volume 14, Number 9—September 2008
Merkel Cell Polyomavirus and Merkel Cell Carcinoma, France
Highlight and copy the desired format.
|EID||Foulongne V, Kluger N, Dereure O, Brieu N, Guillot B, Segondy M, et al. Merkel Cell Polyomavirus and Merkel Cell Carcinoma, France. Emerg Infect Dis. 2008;14(9):1491-1493. https://dx.doi.org/10.3201/eid1409.080651|
|AMA||Foulongne V, Kluger N, Dereure O, et al. Merkel Cell Polyomavirus and Merkel Cell Carcinoma, France. Emerging Infectious Diseases. 2008;14(9):1491-1493. doi:10.3201/eid1409.080651.|
|APA||Foulongne, V., Kluger, N., Dereure, O., Brieu, N., Guillot, B., & Segondy, M. (2008). Merkel Cell Polyomavirus and Merkel Cell Carcinoma, France. Emerging Infectious Diseases, 14(9), 1491-1493. https://dx.doi.org/10.3201/eid1409.080651.|
To the Editor: Merkel cell carcinoma (MCC) is a primary cutaneous neuroendocrine tumor. This aggressive skin cancer is uncommon but increasing in frequency. During 1986–2001, incidence rate tripled; average annual increase was 8% (1). MCC shares epidemiologic features with Kaposi sarcoma, a malignant tumor associated with human herpesvirus 8 infection (2). In particular, MCC affects predominantly immunocompromised patients such as organ transplant recipients (3,4), patients with B-cell lymphoid tumors (5), and patients with AIDS (6). This similarity between MCC and Kaposi sarcoma may support the hypothesis of an infectious origin of MCC.
A new polyomavirus, provisionally named Merkel cell polyomavirus (MCPyV), has been recently identified in tumor tissue from patients with MCC. Furthermore, clonal integration of viral DNA within the tumor genome was observed in most of the cases (7). To assess the implication of MCPyV in MCC, we tested tumor biopsy samples collected from 9 patients with MCC. Patient median age was 65 years, and 2 patients were immunocompromised (patient 1 had a lymphoma, which was treated with rituximab; patient 7 had psoriatic rheumatism, which was treated with corticosteroids and methotrexate). As controls, biopsy samples from 15 patients with diverse proliferative or inflammatory skin or mucosa lesions were tested (Table).
DNA was extracted from fresh tissue samples by using the QIAamp DNA Mini Kit (QIAGEN, Courtaboeuf, France) according to the manufacturer’s instructions. Paraffin was removed from previously formaldehyde-fixed, paraffin-embedded biopsy samples with xylene, and the samples were rehydrated with decreasing concentrations of ethanol. The extracts were tested for MCPyV DNA by PCR using 3 sets of primers initially described by Feng et al. (7) to target the predicted T-antigen (LT1 and LT3 primer pairs) and the viral capsid (VP1 primer pair) coding regions. Extracted DNA (5 μL) was added to 45 μL of the reaction mixture, which contained 5 μL 10× PCR buffer, 10 μL 5× Q-solution (QIAGEN), 2.5 mmol/L MgCl2, 200 μmol/L each dNTP, 2.5 units Taq DNA polymerase (QIAGEN), and 15 pmol of each primer. Touchdown PCR conditions were as follows: 95°C for 5 min followed by 35 cycles of denaturation at 95°C for 30 s; annealing at 61°C (10 cycles), 59°C (10 cycles), and 57°C (15 cycles) for 30 s; extension at 72°C for 1 min; and a final extension step at 72°C for 10 min. Amplification products were subjected to electrophoresis in a 2% agarose, 1× Tris-borate-EDTA gel stained with ethidium bromide and examined under UV light. The sizes of the fragments amplified with the LT1, LT3, and VP1 primers pairs were 439, 308, and 351 bp, respectively. A negative control was included in each experiment; positive samples were confirmed by analyzing a second stored sample aliquot, and the amplified fragments were sequenced by using the same primers used for the amplification. The sequences were submitted to GenBank under accession numbers AM992895–AM992906. Total DNA level in sample extracts was measured by using the LightCycler control DNA kit targeting the β-globin gene (Roche Diagnostics, Meylan, France).
MCPyV sequences were detected in 8 of the 9 patient samples and in none of the control samples (Table). Results for all 8 patients were positive with the LT3 primer pair, whereas they were positive for only 5 with the VP1 primer pair and only 1 with the LT1 primer pair (Table). Because the LT1, VP1, and LT3 primer pairs generate the longer, intermediate, and shorter DNA fragments, respectively, the difference in sensitivity could result from the deleterious effect of formaldehyde fixation on DNA; this effect would increase with the length of the fragment to be amplified. The negative result obtained for patient 8 might suggest that some MCC patients are not infected with MCPyV. This explanation is in accordance with the findings of Feng et al., who reported 80% prevalence of MCPyV in patients with MCC (7). Nevertheless, the single negative result observed in our study might alternatively be explained by insufficient tissue or by DNA degradation through the fixation and embedding process. Indeed, the level of β-globin gene DNA was much lower in the sample from this patient (441 pg/µL) than in samples from the other patients (median 13,500 pg/µL, interquartile range 8,902–19,750 pg/µL).
As observed with human papillomaviruses, a gene disruption caused by viral DNA integration into the host genome might be an alternative hypothesis to explain the lack of amplification of an MCPyV genome region (8). Sequences of the amplified PCR product were 99%–100% identical to those reported by Feng et al. (7), which indicates that this virus is genetically stable.
In summary, we detected MCPyV DNA sequences in 8 of 9 tumor samples from patients with MCC but in none of 15 control samples. Our results confirm the likely association of MCPyV with MCC. The epidemiologic characteristics as well as the carcinogenic role played by this newly discovered virus need to be more thoroughly investigated.
- Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005;89:1–4.
- Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9.
- Penn I, First MR. Merkel’s cell carcinoma in organ recipients: report of 41 cases. Transplantation. 1999;68:1717–21.
- Bensaleh H, Perney P, Dereure O, Guilhou JJ, Guillot B. Merkel cell carcinoma in a liver transplant recipient. Am J Clin Dermatol. 2007;8:239–41.
- Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev. 1999;8:153–8.
- Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet. 2002;359:497–8.
- Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100.
- Das BC, Sharma JK, Gopalakrishna V, Luthra UK. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J Gen Virol. 1992;73:2327–36.
- Table. Merkel cell polyomavirus from 9 patients with Merkel cell carcinoma and 15 control patients, France
Please use the form below to submit correspondence to the authors or contact them at the following address:
Vincent Foulongne, Laboratory of Virology, Hôpital St-Eloi, 34295 Montpellier Cedex 5, France;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 13, 2010
- Page last updated: July 13, 2010
- Page last reviewed: July 13, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)